More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$83.68B
EPS
-7.09
P/E ratio
--
Price to sales
39.96
Dividend yield
--
Beta
1.162536
Previous close
$215.27
Today's open
$219.85
Day's range
$203.84 - $222.43
52 week range
$22.28 - $280.80
show more
CEO
Stéphane Bancel
Employees
4700
Headquarters
Cambridge, MA
Exchange
Nasdaq Global Select
Shares outstanding
404620975
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar Opportunity
Moderna NASDAQ: MRNA is preparing to file a U.S. application for its individualized cancer therapy intismeran by year-end, as executives outlined manufacturing plans and upcoming trial results following positive phase III melanoma data.
MarketBeat • 11 hours ago

Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • 11 hours ago

Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?
MRK ends nemtabrutinib development after phase III safety concerns, shifting focus to its expanding pipeline assets.
Zacks Investment Research • 8 hours ago

Is Moderna's Cancer Vaccine a Game Changer for the Stock?
Intismeran and Keytruda have demonstrated in clinical trials that they can drastically improve outcomes for melanoma patients. The combined treatment has reduced the risk of death and melanoma spreading or returning.
The Motley Fool • Nov 16, 2026

Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
Axsome Therapeutics is experiencing rapid revenue growth driven by its portfolio of central nervous system treatments. Moderna is diversifying its messenger RNA platform into respiratory vaccines and oncology while facing significant net losses.
The Motley Fool • Nov 14, 2026

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
MRNA shares fall as 2027 cost projections raise concerns, while limited visibility into future revenue growth weighs on investor sentiment.
Zacks Investment Research • Nov 13, 2026

Why Moderna Stock Dropped on Thursday
Moderna's revenue guidance for 2026 falls short of analyst targets, meaning a sales miss may be coming. Moderna's earnings might surprise to the upside if its cost-cutting pays off.
The Motley Fool • Nov 12, 2026

Moderna Targets 2027 Cancer Therapy Launch, Raises 2026 Revenue Growth Outlook
Moderna NASDAQ: MRNA is preparing to seek U.S. approval of its individualized cancer treatment intismeran by year-end, with executives aiming for a 2027 launch alongside partner Merck if regulators approve the therapy.
MarketBeat • Nov 12, 2026

The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment
Look at the promising data for Moderna and Merck's experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.
Market Watch • Nov 12, 2026

MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?
Moderna's 3% post-earnings gain reflects stronger overseas COVID-19 sales and higher 2026 guidance, while oncology advances offer growth potential.
Zacks Investment Research • Nov 12, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Moderna Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.